A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...

The firm will evaluate its EGFR-targeted ADC ALX2004 in advanced non-small cell lung, head and neck, esophageal, and colorectal cancers.

Precigen had sought accelerated approval for Papzimeos, but the FDA opted to grant it full approval after reviewing data from a Phase I/II trial.

The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

NEW YORK – A first-in-human Phase I trial is underway testing Atavistik Bio's ATV-1601 in patients with AKT1 E17K-mutated solid tumors, the Cambridge, Massachusetts-based company announced this week.

BioCardia wants to gauge whether it has enough evidence to pursue regulatory approval for CardiAMP in ischemic heart failure.

Under Project Impact, one of four programs backed by $200 million in funds, researchers aim to harmonize EHR data and build an AI model to improve cancer care.